National Cancer Center

National Cancer Center Names Michelle Stack CEO Following Retirement of Long-Time Leader Regina English

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Diagnosis, DNA repair, Brain, Beauty, Education, Research, DNA, Cancer, Prostate cancer, National Cancer Center, Breast cancer, Melanoma, Therapy, NCC, Management

The Board of National Cancer Center is pleased to announce that Michelle Stack has joined as CEO.

Key Points: 
  • The Board of National Cancer Center is pleased to announce that Michelle Stack has joined as CEO.
  • Ms. Stack replaces long-time leader Regina English , who is now Executive Director Emerita and Board member-at-large.
  • “We are delighted to name Michelle as CEO of National Cancer Center,” said Barry Peek , President of the Board.
  • NCC runs six cancer research programs: Aggressive Cancer Project; Fighting Childhood Leukemia; The Breast Cancer Project; Children’s Cancer Project; Prostate Cancer Project and the NCC Project, which funds research showing particular promise in the following areas: brain tumors, melanoma, DNA repair, anti-cancer therapies, gene mutations and targeted therapeutics for breast cancer.

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma

Retrieved on: 
Thursday, March 28, 2024
B-cell lymphoma, Plasma, Shanghai Cancer Center, Rituximab, Apoptosis, Leukemia, International Journal of Hematology, Patient, Hospital, Doxorubicin, Vincristine, Fudan University, CC3, Standard of care, Acute myeloid leukemia, Epidemiology, Biomedical Chromatography, Prednisone, Peripheral T-cell lymphoma, PARP, National Cancer Center, Therapy, MYC, BTK, Safety, BeiGene, CDK9, Cyclophosphamide, DLBCL, Canadian International Council, MCL1, Follicular lymphoma, Pharmaceutical industry

The first patient was dosed in the trial led by prominent Henan Cancer Hospital and Fudan University Shanghai Cancer Center.

Key Points: 
  • The first patient was dosed in the trial led by prominent Henan Cancer Hospital and Fudan University Shanghai Cancer Center.
  • This study will be the first combination trial conducted by a Chinese biotech to combine CDK9 inhibitor and BTK inhibitor targeting DLBCL.
  • The trials of GFH009 treating peripheral T-cell lymphoma and acute myeloid leukemia have entered into phase II stage in China and the U.S. respectively.
  • Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025, Leukemia & Lymphoma, 2021
    3.

Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

Retrieved on: 
Tuesday, March 19, 2024
Medicine, Cervical cancer, Patient, Cancer, HPV16, School, Congress, Gynaecology, Risk, Peking Union Medical College, Woman, LEEP, Safety, Gynecologic Oncology (journal), Pathology, Recurrence, Squamous intraepithelial lesion, Acceleration, Research, Șaeș, SGO, Death, National Cancer Center, Vaccination, Molina Healthcare, Annual general meeting, Health, Obstetrics, Hysterectomy, HSIL, Public health, Infection, Incidence, LSIL, HPV, Bleeding, Physician, Birth control

This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.

Key Points: 
  • This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • Primary endpoint of the study is the proportion of responders at 6 months after the initial treatment.
  • The study is led by Dr. Jinghe Lang, an academician at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.
  • Dr. Linda Wu, Chief Development Officer of Asieris Pharmaceuticals, said, "We are extremely proud of the results from the international multicenter Phase III clinical study of APL-1702.

J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)

Retrieved on: 
Monday, February 26, 2024
NSCLC, Traffic barrier, Severance Hospital, EGFR, ESMO, ASCO, Permeability, Catholic University of Korea, National Cancer Center, Hospital, Asan Medical Center, AACR, Society, University, Seoul National University Hospital, Patient, Clinical trial, Oncology, Mutation, Trial of the century, Cancer, Pharmaceutical industry

J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.

Key Points: 
  • J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.
  • The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer".
  • In August last year, J INTS BIO registered the first patient for the global Phase 1/2 clinical trial of 'JIN-A02' at Severance Hospital in Korea.
  • A J INTS BIO official said, "The global clinical trial for 'JIN-A02' is progressing well and is receiving interest in the global market."

J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)

Retrieved on: 
Monday, February 26, 2024
NSCLC, Traffic barrier, Severance Hospital, EGFR, ESMO, Multimedia, ASCO, Permeability, Catholic University of Korea, National Cancer Center, Hospital, Asan Medical Center, AACR, Society, University, Seoul National University Hospital, Patient, Clinical trial, Oncology, Mutation, Trial of the century, Cancer, Pharmaceutical industry

J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.

Key Points: 
  • J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.
  • The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer".
  • In August last year, J INTS BIO registered the first patient for the global Phase 1/2 clinical trial of 'JIN-A02' at Severance Hospital in Korea.
  • A J INTS BIO official said, "The global clinical trial for 'JIN-A02' is progressing well and is receiving interest in the global market."

Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women's Health Business Unit, Accelerating Strategic Expansion

Retrieved on: 
Tuesday, January 9, 2024
Action plan, E pluribus unum, Woman, Bladder cancer, Marketing, Health, Elimination, Society, Cancer, Cervical cancer, Infection, World Health Organization, Diagnosis, NMIBC, Comparison, Cervical weakness, Multimedia, Death, ASCO, Breast cancer, Eli Lilly, Tislelizumab, Prevalence, MIBC, Neoadjuvant therapy, HPV, Human papillomavirus infection, LSIL, New Drug Application, NMPA, National Health Commission, Central China, Kidney cancer, Women's health, National Cancer Center, PD-1, WHO, Mortality, HSIL, Conditional sentence, Internet, Weak topology, Patient, Senior, State Council, NDA, Incidence, Head, National Medical Products Administration, Miscarriage

This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women's health.

Key Points: 
  • This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women's health.
  • Asieris Pharmaceuticals will leverage both in-house discoveries and external partnerships to enrich its gynecological portfolio, thereby reinforcing its leadership in women's health.
  • In November 2020, the World Health Organization (WHO) released a Global Strategy to Accelerate the Elimination of Cervical Cancer.
  • To further deliver its strategic vision and commitment in the realm of women's health, Asieris Pharmaceuticals has announced the establishment of the Women's Health Business Unit.

AHN Opens New Precision Medicine and Developmental Therapeutics Cancer Clinic at AGH

Retrieved on: 
Thursday, September 7, 2023
Allegheny, Telehealth, University, Cancer Institute, American Board of Internal Medicine, Personalized medicine, Cancer, Development of the human body, Multimedia, Allegheny General Hospital, MS, American Board of Commissioners for Foreign Missions, Oregon Health Plan, Allegheny Health Network, National Cancer Center, Protein, Medical director, AHN, Patient, Physician, Walter Reed National Military Medical Center, Internal medicine, Medicine, Ponce Health Sciences University, Oncology, FDA, Health, Empowerment, Knight Cancer Institute, Disease, Hospital, Pharmaceutical industry, Medical imaging, MD

PITTSBURGH, Sept. 7, 2023 /PRNewswire-PRWeb/ -- The Allegheny Health Network Cancer Institute (AHNCI) announced today that it has established one of the region's first clinics dedicated to precision cancer medicine and has appointed nationally recognized medical oncologist Ariel Lopez-Chavez, MD, MS, to serve as director of the new clinic.

Key Points: 
  • The AHNCI's Precision Medicine and Developmental Therapeutics Clinic focuses on serving adults with metastatic solid tumors, and patients who may need second opinions or are seeking novel treatment options for rare, complex, or advanced-stage cancers.
  • The clinic is based at the AHN Cancer Institute at Allegheny General Hospital in Pittsburgh's North Side and offers both in-person and telemedicine appointments to patients.
  • Because every cancer patient has unique characteristics and preferences, a unique genetic profile, and because cancer is a dynamic, heterogeneous disease, precision therapies are considered the next frontier of cancer treatment.
  • As director of the Precision Medicine and Developmental Therapeutics Clinic, Dr. Lopez-Chavez will lead an innovative program that offers cancer patients access to clinical research trials and novel technologies aimed at maximizing cancer recovery and improving their overall well-being.

Dr. Farouk Shami Celebrates Over 35 Years of Giving Back

Retrieved on: 
Thursday, July 6, 2023
Human, Partnership, City of Hope, Beauty, Diabetes, City of Hope National Medical Center, COVID-19, Cancer, National Cancer Center, Hope, Celebration, Seokyeong University, Funeral, National Cancer Institute, Doctorate, Lone Star College System, Disaster, City, Flood, NASA, Patient, Spirit, Tornado, Cyclone, Knowledge, LG, Resorts World

HOUSTON, Texas, July 6, 2023 /PRNewswire/ -- Chairman and Founder of one of the largest haircare companies in the world, Farouk Systems, Inc., Dr. Farouk Shami has dedicated his life to giving back. He will be honored on July 10th, 2023 as the Spirit of Life Honoree at the upcoming fundraising gala called the City of Hope's Spirit of Life Celebration. The Spirit of Life Award is presented to individuals whose professional and humanitarian accomplishments are worthy of celebration. It is the highest honor given by City of Hope, a National Cancer Institute-designated comprehensive cancer center for diabetes, cancer and other life-threatening diseases.

Key Points: 
  • HOUSTON, Texas, July 6, 2023 /PRNewswire/ -- Chairman and Founder of one of the largest haircare companies in the world, Farouk Systems, Inc., Dr. Farouk Shami has dedicated his life to giving back.
  • Dr. Farouk Shami and Farouk Systems, Inc. have donated millions of dollars and resources to support various philanthropic causes, including COVID-19 relief to health care professionals, first responders, homeless shelters, and food banks.
  • "Giving back is the art of transforming lives and creating a ripple effect of positive change in our world," said Dr. Shami.
  • For those looking to make a difference in the groundbreaking work of City of Hope, donations can be made here.

National Cancer Center Announces Recipients of 2023-24 Research Fellowship Awards

Retrieved on: 
Thursday, June 29, 2023
Research, Philanthropy, Pharmaceutical, Oncology, Hospitals, University, Genetics, Education, Foundation, Clinical Trials, Science, Biotechnology, Health, UPMC Hillman Cancer Center, DNA, Cleveland Clinic, Duke University Hospital, University of Pittsburgh, NCC, Brain, Therapy, Swansea University Medical School, Prostate cancer, Follicular lymphoma, Johns Hopkins School of Medicine, Cancer, Nebraska Medicine, Coronavirus Scientific Advisory Board, Woman, DNA repair, University of Nebraska Medical Center, Breast, University of California, Colon, Harvard Medical School, National Cancer Center, City, Prostate Cancer Foundation, Melanoma, Rockefeller University, Baylor College of Medicine, Diagnosis, New York University Grossman School of Medicine, Tobacco Products Scientific Advisory Committee, Dana–Farber Cancer Institute, Pharmaceutical industry, Interior design, Doctor of Philosophy, New York University

The National Cancer Center is pleased to announce the recipients of its 2023-24 research grant awards, which support research fellows pursuing promising and innovative cancer research.

Key Points: 
  • The National Cancer Center is pleased to announce the recipients of its 2023-24 research grant awards, which support research fellows pursuing promising and innovative cancer research.
  • National Cancer Center is delighted to report that total funding for the 2023-24 year grew by 9.4% to an annual record of $768,000.
  • “For 70 years, National Cancer Center has sought to identify and fund promising projects by the best up-and-coming cancer research fellows,” said Regina English, Executive Director of the National Cancer Center.
  • The NCC runs six cancer research programs: Aggressive Cancer Project; Fighting Childhood Leukemia; the Breast Cancer Project; Children’s Cancer Project; Prostate Cancer Project and the NCC Project, which focuses on research showing particular promise for brain tumors, melanoma, DNA repair, anti-cancer therapies, gene mutations and targeted therapeutics.

Dr. Farouk Shami Honored at the City of Hope's Spirit of Life Celebration

Retrieved on: 
Tuesday, June 6, 2023
Heart, Hair, Diabetes, Education, COVID-19, Cancer, National Cancer Center, Innovation, Master of Kung Fu (comics), Funeral, CHI, National Cancer Institute, Disaster, City, Spirit, LG, Environment, Fashion design

HOUSTON, June 6, 2023 /PRNewswire/ -- Dr. Farouk Shami will be honored as the Spirit of Life Honoree at an upcoming fundraising gala called the City of Hope's Spirit of Life Celebration.

Key Points: 
  • HOUSTON, June 6, 2023 /PRNewswire/ -- Dr. Farouk Shami will be honored as the Spirit of Life Honoree at an upcoming fundraising gala called the City of Hope's Spirit of Life Celebration.
  • It will be held on Monday, July 10th, 2023, at the Zouk Nightclub in Resorts World Las Vegas, Nevada at 6:00 p.m.
  • "Receiving the City of Hope Spirit of Life award is a humbling and deeply meaningful honor.
  • - Dr. Farouk Shami, chairman and founder of Farouk Systems, Inc.